Norethindrone 0.35 mg Daily for Breastfeeding Mothers

Introduction to Norethindrone Use

The American College of Obstetricians and Gynecologists recommends that progestin-only pills, such as norethindrone 0.35 mg, can be used during breastfeeding and may be started immediately postpartum, but should be used with caution in women with a history of gestational diabetes, particularly in Latino populations, due to a two- to threefold increased risk of developing type 2 diabetes 1, 2

Progestin-only pills can be started at any time postpartum, including immediately after delivery, if it is reasonably certain the woman is not pregnant, as recommended by the U.S. Medical Eligibility Criteria 3
The U.S. Medical Eligibility Criteria rates progestin-only pills as category 2 if started <1 month postpartum and category 1 if started ≥1 month postpartum in breastfeeding women, indicating that the advantages generally outweigh the risks 3
No back-up contraception is needed if the woman is <6 months postpartum, amenorrheic, and fully or nearly fully breastfeeding, according to the Centers for Disease Control and Prevention guidelines 3

In Latino breastfeeding women with prior gestational diabetes mellitus, progestin-only oral contraceptives at 0.35 mg/day norethindrone were associated with a two- to threefold increase in diabetes risk, as reported by the American Diabetes Association 1, 2
Progestin-only agents should therefore be used with caution during breastfeeding, particularly in women with prior gestational diabetes, due to the increased risk of developing type 2 diabetes, as recommended by the American College of Obstetricians and Gynecologists 1, 2

Non-hormonal contraceptive methods can be prescribed using standard guidelines and avoid the diabetes risk entirely, as recommended by the American College of Obstetricians and Gynecologists 1, 2
Combination oral contraceptives containing the lowest estrogen doses can be started 6-8 weeks after delivery if the woman is breastfeeding, though these carry different risk profiles, according to the U.S. Medical Eligibility Criteria 1, 2

Consistent daily timing is essential for effectiveness of progestin-only pills, as these have a narrower window for efficacy compared to combination pills, as reported by the Centers for Disease Control and Prevention 3

For breastfeeding women requesting norethindrone 0.35 mg, screen for history of gestational diabetes mellitus, and if present, strongly consider non-hormonal methods first due to 2-3x diabetes risk, as recommended by the American Diabetes Association 1, 2
If no gestational diabetes history or patient accepts diabetes risk after counseling, can initiate immediately postpartum or at any time during breastfeeding, according to the U.S. Medical Eligibility Criteria 3

Women with prior gestational diabetes should have oral glucose tolerance testing repeated at 1 year and at minimum every 3 years thereafter, as recommended by the American Diabetes Association 1, 2
Blood pressure monitoring at each visit is recommended by the American College of Obstetricians and Gynecologists 4
Annual clinical review for stable patients is recommended by the American College of Obstetricians and Gynecologists 4

Schedule a follow-up visit 1 to 3 months after initiating norethindrone to address persistent adverse effects or adherence issues, as recommended by the American Academy of Pediatrics 5, 6
Once established on therapy, perform a clinical review annually, paying particular attention to compliance with daily timing of pill administration, as suggested by the European Society of Human Reproduction and Embryology 7
No routine monitoring tests are required but may be prompted by specific symptoms or concerns, according to the European Society of Human Reproduction and Embryology 7
Monitor for potential drug interactions that may reduce norethindrone effectiveness, including rifampin, barbiturates, and anti-HIV protease inhibitors, as noted by the American Academy of Pediatrics 5

No routine bone density monitoring is indicated for norethindrone 0.35 mg monotherapy, as this is a progestin-only formulation without the bone effects seen with depot medroxyprogesterone acetate, as stated by the European Society of Human Reproduction and Embryology 7
Do not order routine laboratory panels in asymptomatic patients, as these are not indicated and increase healthcare costs without benefit, as recommended by the European Society of Human Reproduction and Embryology 7